The COMBACTE projects were created to meet the challenges of clinical development of antibacterials in response to the worldwide growing problem of antibiotic resistance. In collaboration with other consortia within the IMI New Drugs 4 Bad Bugs (ND4BB) program, the projects will enable more rapid and efficient development and commercialization of much-needed new antibacterial treatments and diagnostic tests.
These challenges have inspired the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) to launch the New Drugs 4 Bad Bugs (ND4BB) program. This Innovative Medicines Initiative (IMI) program represents an unprecedented partnership between industry, academia and biotech organizations to combat antibiotic resistance in Europe by tackling the scientific, regulatory, and business challenges that are hampering the development of new antibiotics. All COMBACTE projects are included within this IMI ND4BB program.
The COMBACTE-NET consortium is dedicated to building strong clinical, laboratory and research networks across Europe that will enable more efficient clinical testing of novel antibacterial drugs; forming the backbone for all COMBACTE clinical studies.
COMBACTE-MAGNET focuses on patients who are critically ill and being treated in intensive-care units. It aims to understand the needs of these patients and doctors and use that knowledge to advance the development of life-saving treatments.
With carbapenem-resistant Gram-negative bacteria on the rise worldwide, COMBACTE-CARE is laying the groundwork for tests of new and more effective treatments for when our current available selection of antibiotics will no longer suffice.
COMBACTE-CDI aims to develop a detailed understanding of the epidemiology and clinical impact of Clostridium difficile infection across Europe. The ultimate goal is to contribute to improved prevention and treatment options for such infections.
Join Europe’s largest clinical and laboratory research network. Collaborate with leaders in the field of antimicrobial resistance. Help overcome the challenges of developing new antibiotics.
Both the European Commission and the EFPIA contribute to the IMI program managing COMBACTE. This guarantees COMBACTE’s independence from commercial interests.
Milestones in boosting the development of novel treatments
2012 Answering IMI’s open call
Pharma industry and academics collaborate closely for the first time ever in COMBACTE-NET
2013 Creating a network
CLIN-Net and LAB-Net start building a network of hospitals and laboratories across Europe
2014 Building the backbone
The creation of a Network Management System and activation of the National Coordinators Network
2015 Performing trials
The launching of COMBACTE-CARE and COMBACTE-MAGNET
2016 Expanding the network
Increasing the number of participating clinical trial sites, and Da Volterra and The Medicines Company coming on board
2019 Finding new financial models for research
Our network has to become self- sustaining, since IMI reduces financial support from 2019, with a total end in late 2021